No Data
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.
Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally
Did Kang Fang Bio, which collapsed in the past, turn around with “head to head” with K medicine?
Investing in health requires a strong heart.
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL